Background <p>Immune checkpoint inhibitors (ICIs) have revolutionized melanoma treatment, with programmed cell death protein 1 (PD-1) inhibitors—alone or in combination with cytotoxic T-lymphocyte–associated protein 4 or lymphocyte-activation gene 3 inhibitors—demonstrating significant efficacy. However, there is a critical lack of robust data to determine the optimal sequencing of these therapies for individual patients. In particular, the role of relatlimab+nivolumab (rela/nivo) within…
International real-world study of combination immunotherapy sequences in metastatic melanoma
Journal for ImmunoTherapy of Cancer | | Guardamagna, M., Lochrin, S. E., Smithy, J. W., Postow, M., Gaudy-Marqueste, C., Malissen, N., Monestier, S., Sullivan, R. J., Czapla, J. A., Lawless, A. R., Pires da Silva, I., Long, G. V., Menzies, A. M., Dimitriou, F., Dummer, R., Marchi, C., Chaurand, A., Dalle, S., Ascierto, P. A., Paone, M., Facchini, B. A., Warrier, G., Lipson, E. J., Erdmann, M., Berking, C., Archambaud, B., Roy, S., Routier, E., Boutros, C., Jamme, P., Belkadi-Sadou, D., Simon-Tillaux, N., Robert, C.
Topics: skin-cancer, cervical-cancer, immunotherapy, chemotherapy, research
Read the full article at Journal for ImmunoTherapy of Cancer